This multicenter, prospective, observational, non-interventional study investigates patients with intracranial hemorrhage under effective anticoagulation with dabigatran or vitamin-K antagonist (VKA). Routine data will be collected during hospitalization. Patients aged 18 years or older under effective therapy with dabigatran and symptomatic intracranial bleeding confirmed by cerebral imaging and treated with idarucizumab will be compared to patients under effective treatment with VKA at the time of onset of the intracranial bleeding. Ninety-five dabigatran patients who provided written informed consent for data transmission will be included. As control group retrospective and anonymized data of 285 VKA patients patients under VKA treatment and admitted to RIC-ICH study centers will be used. For each patient receiving idarucizumab, three patients with intracranial hemorrhage under effective treatment with VKA, will be included (retrospective) in the study. In addition, data of VKA patients will be transferred from the RASUNOA-PRIME and the "Erlanger Hirnblutungs-Register".

Start Date19 Sep 2019

Sponsor / Collaborator

Essen University Hospital

NCT02798107 / WithdrawnNot Applicable

Safety of Potential Paediatric Patients Treated With Idarucizumab: a Non-internventional Chart Review Study

Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises its anticoagulant effect. A clinical development program is ongoing to support marketing authorisation submissions for idarucizumab indicated in patients treated with dabigatran who require emergency surgery/urgent procedures or who have a life-threatening or uncontrolledbleeding when rapid reversal of the anticoagulant effects of dabigatran is required.

Start Date20 May 2019

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT03359889 / CompletedNot Applicable

Post Marketing Surveillance Program of Praxbind Use in India.

This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availability in 2 years at selected centres approved by the regulatory authority.

Start Date26 Dec 2018

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Idarucizumab

100 Translational Medicine associated with Idarucizumab

100 Patents (Medical) associated with Idarucizumab

532

Literatures (Medical) associated with Idarucizumab

01 Jan 2024·The Neurohospitalist

Barriers in Access to Idarucizumab in Ischemic Stroke in a Middle-Income Country

Article

Author: Moreno-Vargas, Eder ; Bayona, Hernán ; Llanos-Leyton, Natalia ; Jaramillo, Eugenia ; Rivillas, Julián ; Amaya, Pablo ; Kafury, Daniel

Background and Purpose:

Current stroke guidelines contraindicate the use of thrombolytics if oral anticoagulants are taken within 48 hours of symptom onset. Idarucizumab is an alternative for patients on dabigatran who experience an acute stroke, so that alteplase may be used. However, this treatment may not be readily available in low/middle-income countries. Our objective is to describe barriers to access to the administration of idarucizumab.

Methods:

We applied a structured survey for health personnel, consulted databases of drug providers, and analyzed reports from the National Pharmacologic Surveillance Data to describe idarucizumab use and the related knowledge among prescribers and the drug distribution in health institutions in Colombia between January 2018 and January 2022.

Results:

In total, 23.6% of the 337 interviewed physicians’ hospitals had access to idarucizumab, and 34.9% of the physicians were unaware of the use of this medication for ischemic stroke. Only 11 private institutions had access to this medication in Colombia. Four male patients with atrial fibrillation received thrombolytics for acute stroke, and two required subsequent mechanical thrombectomy. No fatal complications during hospitalization were observed. Complications included hematuria, hemorrhagic transformation and groin hematoma. None required transfusion or further intervention. All had favorable mRS scores at the 90-day follow-up.

Conclusions:

There are multiple barriers to access idarucizumab in Colombia. The main factors identified are the low medication availability in provincial hospitals and the low medical knowledge. However clinical results in this limited group are satisfactory. Stronger public policies are needed to guarantee optimal stroke treatment in patients on DOACs in Colombia.

19 Dec 2023·Journal of the American Heart Association

Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta‐Analysis

Review

Author: Samaniego, Edgar ; Shim, HyungSub ; Ghannam, Malik ; Al Qudah, Abdullah ; Ortega-Gutierrez, Santiago ; Morán-Mariños, Cristian ; Adams, Harold P ; AlMajali, Mohammad ; Dibas, Mahmoud ; Ghazaleh, Dana ; Galecio-Castillo, Milagros ; Vivanco-Suarez, Juan ; Koul, Prateeka ; Roeder, Hannah ; Leira, Enrique C ; Farooqui, Mudassir ; Khasiyev, Farid ; Rodriguez-Calienes, Aaron

Background:

Intravenous thrombolysis (IVT) is an effective stroke therapy that remains underused. Currently, the use of IVT in patients with recent direct oral anticoagulant (DOAC) intake is not recommended. In this study we aim to investigate the safety and efficacy of IVT in patients with acute ischemic stroke and recent DOAC use.

Methods and Results:

A systematic review and meta‐analysis of proportions evaluating IVT with recent DOAC use was conducted. Outcomes included symptomatic intracranial hemorrhage, any intracranial hemorrhage, serious systemic bleeding, and 90‐day functional independence (modified Rankin scale score 0–2). Additionally, rates were compared between patients receiving IVT using DOAC and non‐DOAC by a random effect meta‐analysis to calculate pooled odds ratios (OR) for each outcome. Finally, sensitivity analysis for idarucizumab, National Institutes of Health Stroke Scale, and timing of DOAC administration was completed. Fourteen studies with 247 079 patients were included (3610 in DOAC and 243 469 in non‐DOAC). The rates of IVT complications in the DOAC group were 3% (95% CI, 3–4) symptomatic intracranial hemorrhage, 12% (95% CI, 7–19) any ICH, and 0.7% (95%CI, 0–1) serious systemic bleeding, and 90‐day functional independence was achieved in 57% (95% CI, 43–70). The rates of symptomatic intracranial hemorrhage (3.4 versus 3.5%; OR, 0.95 [95% CI, 0.67–1.36]), any intracranial hemorrhage (17.7 versus 17.3%; OR, 1.23 [95% CI, 0.61–2.48]), serious systemic bleeding (0.7 versus 0.6%; OR, 1.27 [95% CI, 0.79–2.02]), and 90‐day modified Rankin scale score 0–2 (46.4 versus 56.8%; OR, 1.21 [95% CI, 0.400–3.67]) did not differ between DOAC and non‐DOAC groups. There was no difference in symptomatic intracranial hemorrhage rate based on idarucizumab administration.

Conclusions:

Patients with acute ischemic stroke treated with IVT in recent DOAC versus non‐DOAC use have similar rates of hemorrhagic complications and functional independence. Further prospective randomized trials are warranted.

01 Dec 2023·Hamostaseologie

Article

Author: Möhnle, P ; Trenk, D ; Birschmann, I ; Beyer-Westendorf, J ; Koscielny, J ; Langer, F ; Bauersachs, R

News (Medical) associated with Idarucizumab

17 Aug 2022

·www.biospace.com

High Prevalence Of Respiratory Disorders Is Expected To Boost Growth Prospects For High-Flow Nasal Cannula Market During The Forecast Period

The Acute Respiratory Failures Segment Is Expected To Grow Impressively At A CAGR Of 11.4% Fact.MR – A Market Research and Competitive Intelligence Provider: The global high-flow nasal cannula market is expected to witness a CAGR of 11.8% during the forecast period (2020 – 2025). Technological advancements by key market players are also expected to offer opportunities and new avenues for the market. High prevalence of acute respiratory failures is expected to offer lucrative opportunities for high-value oxygen therapy using high-flow nasal cannula. Other benefits of high-flow nasal cannula are that they deliver a consistent flow of oxygen via the nasal cannula and alleviate upper airway obstruction. Moreover, rise in prevalence of sleep apnea is also anticipated to boost the market growth. High prevalence of non-invasive ventilation and continuous positive airway pressure devices has risen rapidly in home care settings for patients suffering from respiratory diseases. This has also pushed key manufacturers to increase production of devices, thus boosting the market share. For more insights into the Market, Request Brochure of this Report Moreover, increasing population, growing smoking prevalence and degraded air quality have boosted the number of respiratory disease cases. Key players in the market are expanding its production of respiratory support, ventilators and humidification products to hospitals. For instance, ResMed has boosted the production of its devices such as AirCurve 10 bi-level devices to offer some comfort to Covid-19 patients. Key Takeaways: The Acute Respiratory Failures segment is expected to account for around 3/10th of the high-flow nasal cannula market, growing rapidly at a CAGR of 11.4% Rising prevalence of sleep apnea is also expected to boost the market of high-flow nasal cannula. Moreover, market is projected to witness a CAGR of 13.5% during the forecast period. Asia pacific is expected to show impressive growth prospects fro the high-flow nasal cannula market. Moreover, Asia pacific is also expected capture a market share of13.2% Growth Drivers: Covid-19 pandemic has boosted the market aspects for high-flow nasal cannula market. Moreover, owing to its widespread application in the treatment of respiratory diseases, high-flow nasal cannula is gaining traction. Also, as the Covid-19 affects the lungs, high-flow nasal cannula is suitable approaches to aid patients breathe normally. Rising prevalence of respiratory diseases is anticipated to boost the high-flow nasal cannula market during the forecast period. Moreover, growing smoking prevalence have also increased the number of respiratory diseases cases across the globe. Growing acceptance of high-flow nasal cannula treatment among various patients is expected to boost the growth of the market Key players in the market are making significant investments in the product portfolio. Companies are significantly investing in technological advancements to acquire market share. Surge in cases of sleep apnea is also expected to boost the growth of high-flow nasal cannula. For Comprehensive Insights Ask An Analyst Here Competitive Landscape: The global high-flow nasal cannula market is fragmented. Out of the major key players, four of these account for the maximum share, three-tenth of the total market. These four players are BD/CareFusion, Fisher & Paykel Healthcare Limited, Telefax incorporated, and ResMed Inc. Moreover, these players are significantly innovating product portfolios by investing into technological advancements to acquire market presence. For instance, Fisher & Paykel is boosting its production of respiratory support devices, ventilators and humidification products to hospitals. Likewise, ResMed has accelerated its production of its AirCurve 10 bi-level devices to provide some comfort to COVID-19 patients. ResMed Inc. is key player in the market. It offers various products for the treatment of sleep apnea and non-invasive ventilation. Also, flagship products include AirView, ClimateLine Max and myAir for the management of sleep apnea and respiratory disorders. Key Companies Profiled by Fact.MR More Valuable Insights on High-flow nasal cannula market By Component: Air/Oxygen Blend Air Humidifier Single Heated Tube Nasal Cannula Other Consumables By Application: Acute Respiratory Failure Chronic Obstructive Pulmonary Disease (COPD) Carbon Monoxide Toxicity Bronchiectasis Sleep Apnea Other Applications By End-user: Hospitals Long-term Care Centers Ambulatory Care Centers Tomosynthesis Other End-users Key Regions: North America Europe Asia Pacific Latin America Middle East & Africa Get Customization on this Report for Specific Research Solutions Explore Fact.MR’s Coverage on the Healthcare Domain Animal Genetics Market - The development of progressive genetic modification practices is leading to the high production of animals with modified breeds, thereby attracting investments from end users. Antacids Market - Manufacturers in the antacids market are approaching drug formulation techniques through consumer-centric means, in the form of chewable and flavored tablets, to score well in convenience regards. On the back of these factors, the exhaustive study by Fact.MR pegs the global antacids markets to soar to ~US$ 19 Bn by 2025. Antimicrobial Susceptibility Test Market - Rising government initiatives regarding the development of quality hospital infrastructure, on a global level, and surging susceptibility to infectious diseases, are projected to complement the demand for antimicrobial susceptibility tests in diagnostic laboratories and hospitals during the forecast period (2020-2025). Anticoagulant Reversal Drugs Market - Sales of Idarucizumab increased 19% Y-o-Y in 2019 over 2018. However, according to the estimation of a seasoned analyst at Fact.MR, year-over-year sales of the same drug will witness a sharp decrease of 11% in 2026 over 2025. Anticancer Drugs Market - Development of therapeutics with better patient outcomes and lesser side-effects than conventional ones is projected to increase patients’ trust in these drugs, thereby strengthening the growth prospects of the anticancer drugs market. Apheresis Market - Lack of regular blood donors is being countered by private blood collection centres that attract donors through paid plans. In recent times, hospitals are increasing the adoption of apheresis equipment to collect and store required blood components, so as to reduce dependency on private suppliers and blood collection centres. Aptamers Market - Advent of the chemical modification process to increase the nuclease resistance of aptamers, and, in turn, enhance their therapeutic properties creates opportunities galore for players in the aptamer market. Dental 3D Printing Market - Development of customized dental models such as bridges, crowns, implants, and dentures is offering better patient outcomes, and, in turn, boosting the reliance of dentists on printed prosthetics. Behavioural Health Treatment Market - The advent of the on-demand service model underpinning the concepts of tele psychiatry offers the choice to patients to avail home-based treatment services. Besides enhancing the comfort feature, home-based treatment services also offer significant cost benefits and reduced wait times. Assisted Reproductive Technology Market - Studying the relevance of all the crucial dynamics, Fact.MR, in its latest study, forecasts that revenue of the assisted reproductive technology market would witness an annual increase of around 6.3% in 2020. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter

10 Aug 2022

·www.biospace.com

Surge In Number Of Sports Injuries Incidence Is Expected To Push The Growth Of Platelet-Rich Plasma Market By 10% CAGR During The Forecast Period

Dental Technicians Are Progressively Accepting Digital Dentistry, Which Is Offering Lucrative Opportunities For 3D Printer Manufacturers Fact.MR – A Market Research and Competitive Intelligence Provider: The global platelet-rich plasma market is expected to surpass an impressive valuation of around US $ 1.5 Billion surpassing a CAGR of 12% during the assessment period. Platelet-rich plasma is commonly used in healthcare industry, especially in cosmetic surgeries, and orthopedic surgeries. Moreover, Injuries such as rotator cuff, tendon injuries, tennis elbow, and hamstring among others are treated quickly and effectively with the help of platelet-rich plasma therapy. Historically, the platelet-rich plasma market had witnessed a CAGR of 10% and reached a value of US $ 400 Mn. Moreover, surge in sports injuries have also pushed the demand further in coming years. Besides this, plasma is also rapidly used for treatment of medical conditions such as facelift surgeries and erectile dysfunction. These are some of the new application areas in the platelet-rich plasma market. For More Insights on this Market, Get A Sample Report! Apart from this, platelet-rich plasma therapy is very commonly used in cosmetic surgeries. For instance, this is widely used for tapping growth opportunities in hair and skin care. Also, micro-needling, with the help of platelet-rich plasma injections, offers unfolding opportunities to improve skin-texture and appearance. Key Takeaways: United States is anticipated in dominate the market during the forecast period. Moreover, market is expected to witness a CAGR of 9% until 2031. U.K is projected to be the most profitable market for the plasma across Europe owing to high rise in sports injuries. Moreover, market is projected to expand through 2031 registering a growth of 8% CAGR. India is expected to witness an impressive growth prospects for the market during the forecast period. Surge in uptake is observed due to high prevalence of inflammatory diseases. By End-User, Hospitals are expected to register a 10% CAGR during forecast period. Growth Drivers: Surge in number of patients opting for PRP injections is expected to boost the growth of the market. Restraints: Competitive Landscape: The market is moderately competitive and the landscape comprises of key players that are active in the expansion of the global platelet rich-plasma market during the forecast period. Players are also focusing on various strategies to expand product offerings and expand geographic presence. With advancement in technology, new players are entering the market. In February 2021, Atlas Health Medical Group announced plasma-rich platelets availability to its patients. Moreover, in February 2020, EmCyte completed the acquisition of Cellmedix Holdings LLC, that includes proprietary product system, namely Centrepid Platelet Concentrator. To Gain In-Depth Insights on Platelet-Rich Plasma Market, Request Methodology at Key Companies Profiled by Fact.MR Arthrex, Inc. Johnson & Johnson Zimmer Biomet Holdings, Inc. Exactech, Inc. Stryker Corporation Terumo Medical Corporation Biotest Aktiengesellschaft CSL Ltd More Valuable Insights on Platelet-rich Plasma Market Segmentation of Platelet-rich plasma market Product Type Platelet-Rich Plasma Instruments Pure Platelet-Rich Plasma Kits Leucocyte-Rich Platelet-Rich Plasma Kits Platelet-Rich Fibrin Kits Pure Platelet-Rich Fibrin Kits Application Platelet-Rich Plasma for Orthopedic Surgery Platelet-Rich Plasma for Cosmetic Surgery Platelet-Rich Plasma for General Surgery Platelet-Rich Plasma for Neurosurgery Platelet-Rich Plasma for Other Surgeries End User Platelet-Rich Plasma Therapy in Hospitals Platelet-Rich Plasma Therapy in Orthopedic Clinics Platelet-Rich Plasma Therapy in Dermatology Clinics Platelet-Rich Plasma Therapy by Other End Users Interested to Procure The Data? Inquire here Explore Fact.MR's Coverage on the Healthcare Domain- Antacids Market - Antacids Market Analysis Report By Drug Class (Proton Pump Inhibitors, H2 Antagonists), By Distribution Channel (Hospital, Retain Pharmacies), By Formulation, By Region - Global Market Insights 2020-2025 Antimicrobial Susceptibility Test Market - Antimicrobial Susceptibility Test Market Analysis Repot By Product (Kits, Reagents, & Consumables, Automated Test Systems, Culture Media), By Application (Clinical Diagnosis, Drug Discovery and Development), By End User, By Region - Global Insights 2020-2025 Anticoagulant Reversal Drugs Market - Anticoagulant Reversal Drugs Market Analysis Repot By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, Andexxa), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Global Insights 2020-2026 Anticancer Drugs Market - Anticancer Drugs Market Analysis Repot By Drug Type (Targeted Drugs, Cytotoxic Drugs, Hormonal Drugs), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, Colorectal Cancer), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy) - Global Market Forecast 2020-2025 Apheresis Market - Apheresis Market Analysis Repot By Technology (Centrifugation, Membrane Filtration), By Product (Devices, Disposables), By Application (Renal Diseases, Neurology, Haematology, Cancer, Autoimmune Diseases,Cardiovascular Diseases), By Region - Global Market Forecast 2020-2025 Aptamers Market - Aptamers Market Analysis Repot By Application (Research, Diagnostics, Therapeutics), By Selection Technique (SELEX Technique), By Material (Nucleic Acid Aptamers, Peptide Aptamers), By Region - Global Market Forecast to 2010-2025 Dental 3D Printing Market - Dental 3D Printing Market Size, Trend Analysis & Competition Tracking By Material (Metals, Photopolymers, Ceramics), By Application (Dental Implants, Dentures, Crowns & Bridges), By Technology (Vat Photo Polymerization, Fused Deposition Modelling, PolyJet Technology, Selective Laser Sintering) - Global Market Insights 2021 to 2031 Behavioural Health Treatment Market - Behavioural Health Treatment Market Analysis Report By Disorder (Depression, Anxiety, Schizophrenia, Bipolar Disorder, Alcohol Use Disorders, Substance Use Disorders, Eating Disorders, Post-traumatic Stress Disorders), By Service, By Region -Global Forecast 2020-2027 Assisted Reproductive Technology Market - Assisted Reproductive Technology Market Analysis Report By Procedure (Frozen Donor, Frozen Non-donor, Fresh Donor, Fresh Non-donor, Embryo Banking), By Technology (In-vitro Fertilization, Surrogacy, Artificial Insemination), By End User(Fertility Clinics, Hospitals, Other )- Global Market Insights to 2019-2025 Asthma Treatment Market - Asthma Treatment Market Analysis Report By Treatment Type (Long-term Asthma Control Medications, Quick-relief (Rescue) Medications), By Route of Administration(Inhaled, Oral, Intravenous, Subcutaneous), By Region - Global Forecast 2020 to 2027 About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158

ImmunotherapyAcquisition

05 Aug 2022

·www.biospace.com

Rise In Occurrence Of Foot Ulcers, Rheumatoid Arthritis, And Osteoarthritis Across The Globe Is Upscaling Adoption Of Foot Orthotic Insoles And Is Expected To Boost The Growth By 7% CAGR During 2020-2030

Rise In Number Of Diabetic Patients Across The Globe Led To A Y-O-Y Growth Of Over 5% And Reached A Valuation Of US $ 1.3 Billion In 2019 Fact.MR – A Market Research and Competitive Intelligence Provider: The global foot orthotic insoles market was valued at US$ 1.3 Bn in 2019 and is expected to CAGR of 7% till 2030. Number of diabetic patients worldwide is projected to increase to 366 million in 2030. Moreover, foot ulcers are expected to affect 1-4% paitents across the United States. Diabetes mellitus, one of the common degenerative disease, affects 425 million people globally, projected to increase to 629 million by 2045. These factors are expected to boost the growth of the market during forecast period. Various benefits offered by orthotic insoles such as ensuring maximum comfort to patients suffering from foot aliments is expected to support the growth of the market. For More Insights on this Market, Get A Sample Report! Also, orthoses are preferred as this is one of the most appropriate non-invasive approach. Moreover, surge in number of foot disorders from various chronic conditions and external injuries is expected to support the growth of the market. However, initial cost of orthotic insoles is discouraging healthcare companies to invest in these products. Key Takeaways: Foot orthotic insoles sales across the US experienced a Y-o-Y growth of over 5% to reach US $ 1.3 Billion. Moreover, the market is set to further grow at a CAGR of nearly 9% through 2030. By product type, custom soft insoles are expected to experience a 12.1% CAGR across 2020-2030 assessment period. The adult orthotic insoles segment is likely to account for a maximum share of the market, capturing around 70% of the overall revenue during the forecast period. Similarly, the pediatric segment is experiencing growth of 6% through 2030. By material type, ethyl-vinyl-acetate (EVA) based insoles are expected to capture the maximum share of around 1/5th of the total revenue share through 2030. Growth Drivers: Rising prevalence of osteoarthritis, rheumatoid arthritis is upscaling the adoption of orthotic insoles across the globe. Prevalence of inherent foot problems in various developed regions such as France, UK and is expected to boost the growth of the market Countries such as France, UK bear a heavy burden of diabetics, providing lucrative opportunities to insole manufacturers with an opportunity to penetrate the region’s market. Prominent footwear manufacturers in the market are focusing on orthotic insoles. For instance, Bar Schuhe, footwear manufacturer offers insoles with a variety of features and materials ranging from leather to other fabrics. Restraints: Initial cost of purchasing orthotic insoles is acting as a restraint to the market. Moreover, limited awareness related to orthotic insoles in developing nations is expected to act as a challenge for the growth of the market. To Gain In-Depth Insights on Foot Orthotic Insoles Market, Request Methodology at Competitive Landscape: Key players in the market are focusing on multiple expansion strategies to deepen penetration and gather higher market share. Strategies such as product launch, collaborations such as acquisition and mergers are highly adopted. For instance, Aetrex Worldwide Inc., manufactures a host of orthotics products, which are highly suitable for patients affected with plantar fasciitis, foot aches arising from standing professions. In December 2018, Bauerfeind AG had signed a partnership agreement with the National Basketball Association to market its medical knee supporters through the GenuTrain NBA platform In 2018, Cascade Dafo Inc. launched two new product lines: the Fast Fit BugTM and JumpStart SoftbackTM. Key Companies Profiled by Fact.MR Aetrex Worldwide Inc. Bauerfeind AG Acor Orthopedic Amfit Inc. Blatchford Clinical Services Dr. Scholl’s (Bayer) Salts Techstep The Foot Lab Arden Orthotics Ltd. Bolton Bros Cascade Dafo Inc. Algeo Limited Tynor Orthotics Pvt. Ltd. More Valuable Insights on Foot Orthotic Insoles Market Segmentation of Foot Orthotic Insoles Market Product: Prefabricated Custom Rigid/Function Orthotic Insoles Soft/Accommodative Insoles Age Group Adult Pediatric Application Sports & Athletics Medical Personal Comfort Material Thermoplastics Polyethylene Foams Leather Cork Composite Carbon Fibers EVA Gel Others End User Prefabricated Adult Pediatric Custom Adult Pediatric Distribution Channel Drug Stores Hospitals & Specialty Clinics Online Stores Others Region North America Latin America Europe East Asia South Asia Oceania Middle East & Africa (MEA) Interested to Procure The Data? Inquire here Fact.MR’s Domain Knowledge in Healthcare Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions. Explore Fact.MR's Coverage on the Healthcare Domain- Antimicrobial Susceptibility Test Market - Antimicrobial Susceptibility Test Market Analysis Repot By Product (Kits, Reagents, & Consumables, Automated Test Systems, Culture Media), By Application (Clinical Diagnosis, Drug Discovery and Development), By End User, By Region - Global Insights 2020-2025 Anticoagulant Reversal Drugs Market - Anticoagulant Reversal Drugs Market Analysis Repot By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, Andexxa), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Global Insights 2020-2026 Anticancer Drugs Market - Anticancer Drugs Market Analysis Repot By Drug Type (Targeted Drugs, Cytotoxic Drugs, Hormonal Drugs), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, Colorectal Cancer), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy) - Global Market Forecast 2020-2025 Dental 3D Printing Market - Dental 3D Printing Market Size, Trend Analysis & Competition Tracking By Material (Metals, Photopolymers, Ceramics), By Application (Dental Implants, Dentures, Crowns & Bridges), By Technology (Vat Photo Polymerization, Fused Deposition Modelling, PolyJet Technology, Selective Laser Sintering) - Global Market Insights 2021 to 2031 Behavioural Health Treatment Market - Behavioural Health Treatment Market Analysis Report By Disorder (Depression, Anxiety, Schizophrenia, Bipolar Disorder, Alcohol Use Disorders, Substance Use Disorders, Eating Disorders, Post-traumatic Stress Disorders), By Service, By Region -Global Forecast 2020-2027 Assisted Reproductive Technology Market - Assisted Reproductive Technology Market Analysis Report By Procedure (Frozen Donor, Frozen Non-donor, Fresh Donor, Fresh Non-donor, Embryo Banking), By Technology (In-vitro Fertilization, Surrogacy, Artificial Insemination), By End User(Fertility Clinics, Hospitals, Other )- Global Market Insights to 2019-2025 About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158

CollaborateImmunotherapyAcquisition

100 Deals associated with Idarucizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10741	Idarucizumab	V03AB37	DB09264

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhage	US	Boehringer Ingelheim Pharmaceuticals, Inc.	16 Oct 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Venous Thromboembolism	Phase 3	RU	Boehringer Ingelheim GmbH	07 Sep 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISTH2023	Not Applicable	-	3,465	Idarucizumab	wetdxpusmw(cscqyiyelr) = cilppbovso dpnbkrbwgi (ncbhdtzvco, 11.5 - 19.6) View more	-	24 Jun 2023
ISTH2022	Not Applicable	-	6	Idarucizumab	svvtnjfynp(ashzuiorlc) = tmzezoyiow lmanrmadwx (qclvkvrzvf ) View more	Positive	09 Jul 2022
ISTH2022	Not Applicable	-	101	Idarucizumab	kpsautpvgo(omqemdyclm) = ybnqzvxvzv zdgbowymnf (cjxlkkaruh )	-	09 Jul 2022
ISTH2022	Not Applicable	-	46	Idarucizumab	xmcgzqmila(iikknylcjr) = agppwzvzuh mabsmmbvws (pgjhhmousr )	-	09 Jul 2022
NCT03343704 (CTgov)	Phase 3	Hemorrhage	19	Idarucizumab (Group A - Patients With Uncontrolled or Life-threatening Bleeding)	mdxlwtysbk(bsfqwrrjyp) = nyjefooybw hovepboiwv (shfcbjbfdm, upynjmzkfa - jpbzbcgwqy) View more	-	20 Aug 2021
NCT03343704 (CTgov)	Phase 3	Hemorrhage	19	Idarucizumab (Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure)	mdxlwtysbk(bsfqwrrjyp) = zxksdwficq hovepboiwv (shfcbjbfdm, ymfyffwkhs - uvqnrrftny) View more	-	20 Aug 2021
ISC2021	Not Applicable	Hemorrhage	-	Idarucizumab	voyvfgwiui(mrajmbheej) = cnilzkwzhd yhotzagklk (nskweevtti )	-	01 Mar 2021
ISC2021	Not Applicable	Hemorrhage	-	Andexanet Alfa	voyvfgwiui(mrajmbheej) = iblvulbyyl yhotzagklk (nskweevtti )	-	01 Mar 2021
ESC2020	Not Applicable	-	-	Idarucizumab	tdjogpzsbj(pvqrdceacv) = rovdwimalk uekwxcchrt (ojgujjosce, 3.4 - 5.0) View more	-	28 Aug 2020
ISTH2020	Not Applicable	-	7	Idarucizumab	oziaugfnwh(pcdjshtglm) = udklebtluh snszgxlgzk (fokolytkmh )	-	12 Jul 2020
ISTH2020	Not Applicable	-	26	Praxbind 5g	ziznezunyt(uknxmfreez) = ycyzeahnvm yklvvuwhuu (mqtcxgywwv )	-	12 Jul 2020
ISTH2020	Not Applicable	-	26	Praxbind 2.5g	ziznezunyt(uknxmfreez) = odryabmcjc yklvvuwhuu (mqtcxgywwv )	-	12 Jul 2020
NCT02946931 (Pubmed)	Not Applicable	-	262	Idarucizumab	pipsrfhqtp(ieggkulnrm) = axomyjxolz sdflfxuocp (bxbbbethse )	-	01 Jun 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis